Enzolytics Inc. (ENZC) Research

Enzolytics Inc., a biopharmaceutical company based in Plano, Texas, is dedicated to the development and commercialization of its specialized protein-based therapies. Its primary focus is on addressing severe infectious illnesses. The company possesses patented anti-HIV treatments that have successfully completed clinical testing. Additionally, Enzolytics has developed a unique methodology for manufacturing human IgG1 monoclonal antibodies, intended to provide non-toxic passive immunotherapy against various infectious diseases. A significant achievement includes the creation of a proprietary cell line, specifically engineered to produce human monoclonal antibodies that effectively target and neutralize the human immunodeficiency virus (HIV).

Market snapshot

Symbol
ENZC
Price
$0.00
Day change
0.00%
Market cap
$3.9M
P/E ratio
-9.24x
52-week range
0.0002-0.0013
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Biocure Technology Inc. (BICTF)
  • Biomind Labs Inc. (BMNDF)
  • Chia Tai Enterprises International Limited (CAIHF)
  • Cann American Corp. (CNNA)
  • Ember Therapeutics, Inc. (EMBT)
  • International Stem Cell Corporation (ISCO)
  • Medigene AG (MDGEF)
  • Neon Bloom, Inc. (NBCO)

Open Enzolytics Inc. (ENZC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.